IDNAvsIGSB
iShares Genomics Immunology and Healthcare ETF against iShares 1-5 Year Investment Grade Corporate Bond ETF — the fee, the flows, the book, and a year head-to-head.
Head to head
| IDNA | IGSB | |
|---|---|---|
| Expense ratio | 0.47% | 0.040% |
| Assets | $299M | $23.4B |
| Net flow, 1 month | +$20M | +$296M |
| Net flow, 1 year | +$75M | +$2.7B |
| Return, YTD | +59.0% | -3.3% |
| Return, 1 year | +71.1% | -3.4% |
| Avg daily volume | 185K | 4.9M |
| Holdings | 63 | 3892 |
| Listed | Jun 11, 2019 | Jan 5, 2007 |
| Options market | Yes | Yes |
MARKED CELLS LEAD ON THAT LINE · LOWER FEE, LARGER ASSETS, STRONGER FLOWS & RETURNS